ENO2 and acute lymphoblastic leukemia: Based on this cutoff value, 48 patients with ALL (68.6%) were classified into the high-NSE-level or elevated NSE group (>15.2 ng/mL), while the remaining 22 patients (31.4%) were classified into the low-NSE-level or normal NSE group (≤15.2 ng/mL).